| scholarly article | Q13442814 |
| P2093 | author name string | Roger Abramino Levy | |
| Adriana Danowski | |||
| Andreas Funke | |||
| Danieli Castro Oliveira de Andrade | |||
| Jozelia Rêgo | |||
| P2860 | cites work | Catastrophic antiphospholipid syndrome: The current management approach | Q39019618 |
| Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients | Q43150848 | ||
| False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome | Q45731891 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. | Q51289629 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Endothelial and platelet microparticles in patients with antiphospholipid antibodies. | Q53671788 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| Antiphospholipid syndrome | Q55891386 | ||
| Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients | Q57907773 | ||
| Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. | Q64897464 | ||
| Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding | Q81541158 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time | Q84349009 | ||
| Renal involvement in antiphospholipid syndrome | Q86984388 | ||
| Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism | Q87211442 | ||
| New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome | Q87417887 | ||
| Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 | ||
| Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials | Q27023414 | ||
| The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature | Q27497485 | ||
| Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review | Q28081765 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome | Q33387161 | ||
| Diagnosis and classification of the antiphospholipid syndrome | Q33412887 | ||
| Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients | Q33502956 | ||
| Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers | Q33766670 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients | Q34435380 | ||
| Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. | Q34749444 | ||
| Guidelines for the treatment of antiphospholipid syndrome | Q34821893 | ||
| Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. | Q35925359 | ||
| Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis | Q36093916 | ||
| Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome | Q36778271 | ||
| Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome | Q37318783 | ||
| Obstetric antiphospholipid syndrome | Q37946086 | ||
| Perioperative care for patients with rheumatic diseases | Q37956135 | ||
| Management of obstetric antiphospholipid syndrome | Q37959314 | ||
| Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature | Q38038986 | ||
| Use of new oral anticoagulants in antiphospholipid syndrome | Q38104683 | ||
| Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature | Q38122121 | ||
| Patients with disorders of thrombosis and hemostasis | Q38158536 | ||
| Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. | Q38159868 | ||
| Perioperative management of antiphospholipid antibody-positive patients | Q38211785 | ||
| Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. | Q38280730 | ||
| Antiphospholipid syndrome and the heart: a case series and literature review | Q38280840 | ||
| Antiphospholipid syndrome: an update | Q38410376 | ||
| Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. | Q38416654 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 140-149 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Jornal Vascular Brasileiro | Q50521697 |
| P1476 | title | A importância de reconhecer a síndrome antifosfolípide na medicina vascular. | |
| P478 | volume | 16 |
Search more.